Dr. Edwin Medilabs Pvt. Ltd.
DEMLDEMLDEML
(M) : +91 8427243000
contact@bidubiotech.com
Sector-118, S.A.S Nagar Mohali, Punjab (IN) 140301
DEMLDEMLDEML

Our Story

Allien Pharmaceuticals was
established in 2008

Edwin Healthcare Started in 2013

Nutraceuticals Manufacturing Unit

Started Edwin Biotech(Beta Lactum) in 2015

State of Art Manufacturing Unit

DEML Healthcare is a privately held, multinational company headquartered in (Mohali) Punjab, India. Established in 2016,

State of Art Manufacturing Unit

2020

Ayurvedic and Nutraceuticals Manufacturing Unit Edwin Healthcare and Ayurveda, Channalon Kurali Punjab

Bidu Biotech Established in 2010

Started Dr. Edwin Lab (Non-Beta) in 2014

State of Art Manufacturing Unit

DR Darwin Lab in 2017

State of Art Manufacturing Unit-INJECTABLE Dry/Liquid

2020

WHO Compliance Manufacturing Beta/Non-Beta Lactum Plant DR Edwin Medilabs Pvt Ltd, Plot No. B-29, Industrial Focal Point, Chanalon, Kurali, Mohali, Punjab, India, Pin 140103 (For export universal plant, large scale orders, and R&D lab

Our History

Dr. Edwin Medilabs Pvt. Ltd. is a privately held company headquartered in Punjab, India. DEML is a leading manufacturer of pharmaceutical drugs, injections, soaps, and an end-to-end solution provider for the pharmaceutical industry for formulations related services. DEML is Punjab’s single largest Contract Research and Manufacturing (CRAMS) company. The organization offers a comprehensive range of services starting from formulation development to market launch all en suite.

DEML’s 3 state-of-the-art facilities are equipped to produce all modern dosage forms — tablets, hard-gelatin capsules, powder in sachets, liquid syrups and suspensions, injections, eyelear drops, ointments, creams, gels, lotions, ayurveda
and herbal preparations, nutraceutical and cosmetic preparations and many more.

DEML has emerged as an integrated solution provider for companies seeking specific development and business goals. Along with its core service offering, the company offers advanced solutions for formulation development and testing. DEML group’s total revenue stood at more than INR 7Scr in the financial year 2020-21, growing at a rate of more than 30% over the past year.

At vero eos et accusamus et iusto odio digni goikussimos ducimus qui to bonfo blanditiis praese. Ntium voluum deleniti atque.

Melbourne, Australia
(Sat - Thursday)
(10am - 05 pm)
X